与相关的衍生碳点用于pH触发的药物释放
Priyanka Mathur1, Meera Mori1, Foram Patel2
1Department of Chemistry, Faculty of Science, The Maharaja Sayajirao University of Baroda, Vadodara, Gujarat 390002, India.
ACS omega
|June 9, 2025
概括
衍生碳点 (LCD) 与胺结合,为生物成像和药物输送创造了新的超分子架构. 这些与胺相关的碳点 (CL-LCD) 显示出有望用于向癌症治疗和瘤可视化.
科学领域:
- 材料科学 材料科学 材料科学
- 纳米技术 纳米技术
- 生物医学工程 生物医学工程
背景情况:
- 来自诸如之类的自然来源的碳点为先进材料提供了可持续的构建模块.
- 库尔库米诺酸,具有光学性质的天然化合物,可用于功能化纳米材料.
- 超分子架构对于开发有针对性的药物输送系统和先进的成像剂至关重要.
研究的目的:
- 设计和合成超分子架构使用衍生碳点 (LCD) 和curcuminoids.
- 评估这些架构在生物成像和药物输送应用中的潜力.
- 为了研究含有甲铁的CL-LCD的抗癌活性和药物释放概况.
主要方法:
- 通过链接合成与胺相关的碳点 (CL-LCDs).
- 使用高分辨率传输电子显微镜 (HR-TEM) 和现场发射炮扫描电子显微镜 (FEG-SEM) 进行CL-LCD的表征.
- 封装甲索特酸 (MTX) 并评估其在不同pH条件下的持续释放.
- 对HeLa细胞的抗癌活性和药物释放后光发光恢复的评估.
主要成果:
- CL-LCDs-1显示了适合生物成像应用的光学特性.
- 所有CL-LCD衍生物的大小约为10纳米,适合药物输送.
- 含有甲托雷克萨特的CL-LCD显示持续的药物释放,CL-LCDs-3显示在7天后在pH 5.5下释放27.50%.
- 装有MTX的CL-LCDs-1对HeLa细胞表现出显著的抗癌活性,在药物释放后恢复光发光.
结论:
- 与素结合的碳点形成了有效的超分子架构,用于双重生物成像和药物输送.
- 开发的CL-LCD显示了针对性抗癌疗法和实时瘤成像的潜力.
- 可持续的起源和CL-LCD的多功能性质突显了他们在纳米医学中的承诺.
相关概念视频
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
Modified-Release Drug Delivery Systems: Classification
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Oral Drug Delivery Systems: Delayed-Release Systems
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...


